Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression
2019 ◽
Vol 243
◽
pp. 516-524
◽
2008 ◽
Vol 28
(1)
◽
pp. 117-118
2018 ◽
Vol 25
(7)
◽
pp. 1592-1603
◽
2019 ◽
Vol 259
◽
pp. 15-20
◽